Immuneering (IMRX) Retained Earnings (2020 - 2024)
Historic Retained Earnings for Immuneering (IMRX) over the last 5 years, with Q3 2024 value amounting to -$206.2 million.
- Immuneering's Retained Earnings fell 3918.92% to -$206.2 million in Q3 2024 from the same period last year, while for Sep 2024 it was -$206.2 million, marking a year-over-year decrease of 3918.92%. This contributed to the annual value of -$163.3 million for FY2023, which is 4870.49% down from last year.
- As of Q3 2024, Immuneering's Retained Earnings stood at -$206.2 million, which was down 3918.92% from -$191.6 million recorded in Q2 2024.
- Immuneering's Retained Earnings' 5-year high stood at -$25.7 million during Q4 2020, with a 5-year trough of -$206.2 million in Q3 2024.
- In the last 5 years, Immuneering's Retained Earnings had a median value of -$109.8 million in 2022 and averaged -$112.1 million.
- As far as peak fluctuations go, Immuneering's Retained Earnings tumbled by 13029.85% in 2021, and later tumbled by 3918.92% in 2024.
- Over the past 5 years, Immuneering's Retained Earnings (Quarter) stood at -$25.7 million in 2020, then plummeted by 130.3% to -$59.3 million in 2021, then tumbled by 85.22% to -$109.8 million in 2022, then plummeted by 48.7% to -$163.3 million in 2023, then decreased by 26.33% to -$206.2 million in 2024.
- Its last three reported values are -$206.2 million in Q3 2024, -$191.6 million for Q2 2024, and -$177.6 million during Q1 2024.